首页> 外文期刊>European journal of clinical pharmacology >Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus
【24h】

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus

机译:他克莫司治疗的肾移植患者新发糖尿病移植后常见的2型糖尿病遗传危险因素分析

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose New-onset diabetes after transplantation (NODAT) is a major complication after kidney transplantation. The risk factors for NODAT include the use of calcineurin inhibitors as part of the immunosuppressive regimen, among which tacrolimus has the most pronounced diabetogenic effect. Both NODAT and type 2 diabetes mellitus (T2DM) share several risk factors. Recent studies have identified a number of common genetic variants associated with increased risk of T2DM. Here we report the results of our study on the potential effect of single nucleotide polymorphisms (SNPs) previously associated with T2DM on the risk of NODAT in kidney transplant patients medicated with tacrolimus. Methods Seven SNPs in six genes known to increase the risk of T2DM in Caucasians were genotyped by means of TaqMan assays in 235 kidney transplant patients medicated with tacrolimus: rs4402960 and rs1470579 in IGF2BP2; rs1111875 in HHEX; rs10811661 upstream of CDKN2A/B; rs13266634 in SLC30A8; rs1801282 in PPARG; rs5215 in KCNJ11. The TCF7L2 rs7903146 SNP was also included in the multivariate analysis. Results None of the analyzed SNPs was significantly associated with the risk of NODAT. However, the IGF2BP2 rs4402960 T allele was present significantly more frequently among patients diagnosed with NODAT more than 2 weeks after transplantation (p=0.048). Mean (± standard deviation) number of the analyzed alleles tended to be lower in patients without NODAT (6.19±1.71) than in NODAT patients (6.58±1.1.95; p=0.09) and significantly lower compared to late-onset NODAT patients (7.03±1.88; p=0.018). Multivariate analysis confirmed the significance of 'diabetogenic' allele number in late-onset NODAT development [odds ratio (OR) 1.37, 95 % confidence interval (CI) 1.05-1.78; p=0.017]. Additionally, individuals carrying >7 of the analyzed 'diabetogenic' alleles were at a significantly higher risk of NODAT (OR 2.17, 95 % CI 1.18-3.99; p=0.015). Conclusions Complex analysis of genotypes increasing the risk of diabetes may lead to the identification of NODAT susceptibility predictors.
机译:目的移植后新发糖尿病(NODAT)是肾脏移植后的主要并发症。 NODAT的危险因素包括使用钙调神经磷酸酶抑制剂作为免疫抑制方案的一部分,其中他克莫司具有最明显的致糖尿病作用。 NODAT和2型糖尿病(T2DM)均具有多个风险因素。最近的研究已经确定了许多与T2DM风险增加相关的常见遗传变异。在这里,我们报告了先前与T2DM相关的单核苷酸多态性(SNP)对他克莫司治疗的肾脏移植患者NODAT风险的潜在影响的研究结果。方法采用TaqMan分析法对235名他克莫司治疗的肾移植患者中的六个已知增加白种人T2DM风险的基因中的七个SNP进行基因分型:IGF2BP2中的rs4402960和rs1470579; HHEX中的rs1111875; CDKN2A / B上游的rs10811661; SLC30A8中的rs13266634; PPARG中的rs1801282; KCNJ11中的rs5215。 TCF7L2 rs7903146 SNP也包括在多变量分析中。结果分析的SNPs均与NODAT风险无显着相关性。但是,在移植后超过2周的诊断为NODAT的患者中,IGF2BP2 rs4402960 T等位基因的出现频率更高(p = 0.048)。没有NODAT的患者(6.19±1.71)的分析等位基因的平均数(±标准差)倾向于低于NODAT的患者(6.58±1.1.95; p = 0.09),并且比迟发性NODAT的患者要低( 7.03±1.88; p = 0.018)。多变量分析证实了“致糖尿病”等位基因数目在迟发性NODAT发生中的重要性[几率(OR)1.37,95%置信区间(CI)1.05-1.78; p = 0.017]。此外,携带> 7个“糖尿病成因”等位基因的个体处于NODAT的风险明显更高(OR 2.17,95%CI 1.18-3.99; p = 0.015)。结论对增加糖尿病风险的基因型进行复杂分析可能会导致NODAT易感性指标的确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号